Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Figure 2

Comparison of LIFETEST of PFS between IMRT concurrent with sorafenib (group A) and IMRT alone (group B).